Dapivirine vs Doravirine

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV reverse transcriptase · full HIV pipeline

Dapivirine · Dapivirine Vaginal Ring

Marketed by Population Council and partners

Phase 3 in HIVsmall molecule
Reliable signal

NCT01617096 · Phase 3 · completed

This Phase 3 trial randomized 2,629 women to a monthly dapivirine vaginal ring or a placebo ring, with participants and investigators blinded, and used HIV-1 seroconversion as the primary endpoint. The published analysis shows a 27% lower incidence of HIV-1 infection with dapivirine (95% CI 1 to 46; P = 0.046). The design is robust and the primary comparison is statistically significant, although the effect was smaller where adherence was low.

Reported efficacy

Efficacy as Determined by the Proportion of Women in Each Arm With HIV-1 Seroconversion After 120 Endpoints Are Observed in the Trial. (minimum of 12 months and a maximum of 14 months per participant); The Number of Participants That Experienced Grade 2, 3, 4 and Serious Adverse Events Over the Investigational Product Used Period (25 mg Dapivirine Administered in a Silicone Elastomer Vaginal Matrix Ring (DVR), Inserted Once Every 4 Weeks). (minimum of 12 months and a maximum of 14 months per participant): HIV-1 seroconversion: 71/1313 dapivirine vs 97/1313 placebo; incidence 27% lower with dapivirine (95% CI 1 to 46; P = 0.046), 37% lower after exclusion of two low-adherence sites (P = 0.007). (met)

Result source: NCT01617096

Doravirine · Pifeltro

Marketed by Merck & Co.

Approved in HIVsmall molecule
Reliable signal

NCT02275780 · Phase 3 · completed

This was a randomized, double-blind, active-controlled Phase 3 trial with 769 enrolled adults (385 doravirine, 384 darunavir/ritonavir). The primary endpoint was virologic suppression (HIV-1 RNA <50 copies/mL) at Week 48, a hard clinical endpoint. The non-inferiority comparison was met: the difference was 3.9 percentage points (95% CI -1.6 to 9.4), with the lower bound above the prespecified -10% margin. The trial therefore provides strong evidence that doravirine is non-inferior to darunavir/ritonavir.

Next expected readout: November 2026 · NCT04892654 (registry estimate)

Reported efficacy

Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48; Percentage of Participants With Tier-1 Neuropsychiatric Adverse Events (AEs) (Up to Week 48): Week 48 HIV-1 RNA <50 copies/mL: 84.3% doravirine/tenofovir/lamivudine vs 80.8% ATRIPLA; treatment difference 3.537 percentage points (95% CI -1.951 to 9.026), with a non-inferiority margin of -10. Tier-1 neuropsychiatric events: dizziness 8.8% vs 37.1% (difference -28.3, p<0.001); sleep disorders/disturbances 12.1% vs 25.5% (difference -13.5, p<0.001); altered sensorium 4.4% vs 8.2% (difference -3.8, p=0.033). (met)

Result source: NCT02403674

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointDapivirineDoravirine
HIV-1 RNA below 50 copies/mL (week 48)—Trial running · NCT0625050483.8% vs 79.9%vs Daurunavir + Ritonavir100 mg · wk 48 · n 383NCT02275780
3 other results
  • 84.3% vs 80.8% wk 48 · n 364 · Phase 3 · primary NCT02403674
  • 73.1% vs 66% 100 mg · wk 96 · n 379 · Phase 3 · secondary NCT02275780
  • 77.5% vs 73.6% wk 96 · n 364 · Phase 3 · secondary NCT02403674
HIV-1 RNA 50 copies/mL or more (week 48)—Trial running · NCT062505040% vs 1.5%vs Baseline Antiretroviral Therapy (ART)wk 48 · n 336NCT04223778
CD4 count, change (week 48)—Trial running · NCT06250504224.1 vs 206.7vs Daurunavir + Ritonavir100 mg · wk 96 · n 342NCT02275780
14 other results
  • 192.7 vs 185.6 100 mg · wk 48 · n 363 · Phase 3 · secondary NCT02275780
  • 217.1 vs 319.9 100 mg/0.75 mg · wk 96 · n 159 · Phase 3 · secondary NCT04233879
  • 182.4 vs 233.5 100 mg/0.75 mg · wk 48 · n 263 · Phase 3 · secondary NCT04233879
  • 0.5 vs 66.3 wk 144 · n 170 · Phase 3 · secondary NCT04223791
  • 5.4 vs 62.7 wk 96 · n 273 · Phase 3 · secondary NCT04223791
  • -19.7 vs 40.5 wk 48 · n 301 · Phase 3 · secondary NCT04223791
  • 239.6 vs 350.9 100 mg/0.75 mg · wk 144 · n 24 · Phase 3 · secondary NCT04233879
  • 259.2 vs 263.6 100 mg · wk 96 · n 95 · Phase 2 · secondary NCT01632345
  • 191.9 vs 194.5 100 mg · wk 48 · n 102 · Phase 2 · secondary NCT01632345
  • 133.6 vs 121.1 100 mg · wk 24 · n 41 · Phase 2 · secondary NCT01632345
  • 152.3 vs 146 100 mg · wk 24 · n 106 · Phase 2 · secondary NCT01632345
  • 140.7 vs 121.1 200 mg · wk 24 · n 40 · Phase 2 · secondary NCT01632345
  • 112.9 vs 121.1 50 mg · wk 24 · n 41 · Phase 2 · secondary NCT01632345
  • 154.1 vs 121.1 25 mg · wk 24 · n 38 · Phase 2 · secondary NCT01632345

HIV-1 RNA below 50 copies/mL (week 48)

Dapivirine
—Trial running · NCT06250504
Doravirine
83.8% vs 79.9%vs Daurunavir + Ritonavir100 mg · wk 48 · n 383NCT02275780
3 other results
  • 84.3% vs 80.8% wk 48 · n 364 · Phase 3 · primary NCT02403674
  • 73.1% vs 66% 100 mg · wk 96 · n 379 · Phase 3 · secondary NCT02275780
  • 77.5% vs 73.6% wk 96 · n 364 · Phase 3 · secondary NCT02403674

HIV-1 RNA 50 copies/mL or more (week 48)

Dapivirine
—Trial running · NCT06250504
Doravirine
0% vs 1.5%vs Baseline Antiretroviral Therapy (ART)wk 48 · n 336NCT04223778

CD4 count, change (week 48)

Dapivirine
—Trial running · NCT06250504
Doravirine
224.1 vs 206.7vs Daurunavir + Ritonavir100 mg · wk 96 · n 342NCT02275780
14 other results
  • 192.7 vs 185.6 100 mg · wk 48 · n 363 · Phase 3 · secondary NCT02275780
  • 217.1 vs 319.9 100 mg/0.75 mg · wk 96 · n 159 · Phase 3 · secondary NCT04233879
  • 182.4 vs 233.5 100 mg/0.75 mg · wk 48 · n 263 · Phase 3 · secondary NCT04233879
  • 0.5 vs 66.3 wk 144 · n 170 · Phase 3 · secondary NCT04223791
  • 5.4 vs 62.7 wk 96 · n 273 · Phase 3 · secondary NCT04223791
  • -19.7 vs 40.5 wk 48 · n 301 · Phase 3 · secondary NCT04223791
  • 239.6 vs 350.9 100 mg/0.75 mg · wk 144 · n 24 · Phase 3 · secondary NCT04233879
  • 259.2 vs 263.6 100 mg · wk 96 · n 95 · Phase 2 · secondary NCT01632345
  • 191.9 vs 194.5 100 mg · wk 48 · n 102 · Phase 2 · secondary NCT01632345
  • 133.6 vs 121.1 100 mg · wk 24 · n 41 · Phase 2 · secondary NCT01632345
  • 152.3 vs 146 100 mg · wk 24 · n 106 · Phase 2 · secondary NCT01632345
  • 140.7 vs 121.1 200 mg · wk 24 · n 40 · Phase 2 · secondary NCT01632345
  • 112.9 vs 121.1 50 mg · wk 24 · n 41 · Phase 2 · secondary NCT01632345
  • 154.1 vs 121.1 25 mg · wk 24 · n 38 · Phase 2 · secondary NCT01632345
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Dapivirine: 4 of 4 rows · Doravirine: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDapivirineDoravirine
Dropout rate
11.3%25 mg DVR inserted once every 4 weeksa
NCT01617096 · Phase 3 · monotherapy
show 9 more results
9.9%25 mg
NCT02862171 · Phase 3
3.6%25 mg vaginal matrix ring
NCT02858037 · Phase 3 · registry result, not featured evidence
—
NCT03593655 · Phase 2 · registry result, not featured evidence
5.5%
NCT02028338 · Phase 2 · registry result, not featured evidence
2.8%
NCT02010593 · Phase 2 · registry result, not featured evidence
20.9%Dapivirine Gel 4759
NCT00799058 · Phase 1/2 · registry result, not featured evidence
23.3%Dapivirine Gel 4789
NCT00799058 · Phase 1/2 · registry result, not featured evidence
10.5%
NCT03239483 · Phase 1 · registry result, not featured evidence
31%
NCT01539226 · Phase na · registry result, not featured evidence
24.2%100 mgb
NCT02275780 · Phase 3 · combination
show 44 more results
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (From Day 1) at B
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch at Week 96 Base
NCT02403674 · Phase 3 · HIV · phase 3
19.6%MK-1439A (DOR/3TC/TDF From Day 1)
NCT02403674 · Phase 3 · HIV · phase 3
10%Cohort 1: DOR
NCT03332095 · Phase 1/2
2.2%Cohort 2: DOR/3TC/TDF
NCT03332095 · Phase 1/2 · combination
20.4%100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
8.2%100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
0%
NCT04689737 · Phase 4 · registry result, not featured evidence
30.4%DOR/ISL
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 0 - Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 48-Week 9
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 96-Week 1
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Open-Label Extension Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Post-Treatment Follow-Up
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
80.2%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—Group 1: DOR/ISL Weeks 0-48
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 1: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
17%Group 1: Doravirine/Islatravir (DO
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 2: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
42.9%DOR/ISL + ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
—DOR/ISL+ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
33.3%DOR/ISL: Treatment Naive Cohort
NCT04295772 · Phase 2 · registry result, not featured evidence
—DOR/ISL: Treatment Naive Cohort Ex
NCT04295772 · Phase 2 · registry result, not featured evidence
43.6%DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
—DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
—100 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—50 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
28.6%
NCT04900974 · Phase 1 · registry result, not featured evidence
0%
NCT02715700 · Phase 1 · registry result, not featured evidence · combination
0%200 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—25 mg DVR inserted once every 4 weeksa
NCT01617096 · Phase 3 · monotherapy
show 9 more results
—25 mg
NCT02862171 · Phase 3
—25 mg vaginal matrix ring
NCT02858037 · Phase 3 · registry result, not featured evidence
—
NCT03593655 · Phase 2 · registry result, not featured evidence
—
NCT02028338 · Phase 2 · registry result, not featured evidence
—
NCT02010593 · Phase 2 · registry result, not featured evidence
4.7%Dapivirine Gel 4759
NCT00799058 · Phase 1/2 · registry result, not featured evidence
0%Dapivirine Gel 4789
NCT00799058 · Phase 1/2 · registry result, not featured evidence
—
NCT03239483 · Phase 1 · registry result, not featured evidence
0%
NCT01539226 · Phase na · registry result, not featured evidence
1.6%100 mgb
NCT02275780 · Phase 3 · combination
show 44 more results
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Only (From Day 1) at B
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
—DOR/3TC/TDF Switch at Week 96 Base
NCT02403674 · Phase 3 · HIV · phase 3
3%MK-1439A (DOR/3TC/TDF From Day 1)
NCT02403674 · Phase 3 · HIV · phase 3
—Cohort 1: DOR
NCT03332095 · Phase 1/2
—Cohort 2: DOR/3TC/TDF
NCT03332095 · Phase 1/2 · combination
—100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
—100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
—
NCT04689737 · Phase 4 · registry result, not featured evidence
—DOR/ISL
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 0 - Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 48-Week 9
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Base Study Week 96-Week 1
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Open-Label Extension Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—DOR/ISL: Post-Treatment Follow-Up
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
—Group 1: DOR/ISL Weeks 0-48
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 1: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 1: Doravirine/Islatravir (DO
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 2: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
—DOR/ISL + ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
—DOR/ISL+ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
—DOR/ISL: Treatment Naive Cohort
NCT04295772 · Phase 2 · registry result, not featured evidence
—DOR/ISL: Treatment Naive Cohort Ex
NCT04295772 · Phase 2 · registry result, not featured evidence
—DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
—DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
—100 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—50 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
—
NCT04900974 · Phase 1 · registry result, not featured evidence
—
NCT02715700 · Phase 1 · registry result, not featured evidence · combination
—200 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
—25 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
Serious AEs
8.8%25 mg DVR inserted once every 4 weeksa
NCT01617096 · Phase 3 · monotherapy
show 9 more results
2.1%25 mg
NCT02862171 · Phase 3
1.4%25 mg vaginal matrix ring
NCT02858037 · Phase 3 · registry result, not featured evidence
0%
NCT03593655 · Phase 2 · registry result, not featured evidence
2.7%
NCT02028338 · Phase 2 · registry result, not featured evidence
1.4%
NCT02010593 · Phase 2 · registry result, not featured evidence
2.3%Dapivirine Gel 4759
NCT00799058 · Phase 1/2 · registry result, not featured evidence
0%Dapivirine Gel 4789
NCT00799058 · Phase 1/2 · registry result, not featured evidence
0%
NCT03239483 · Phase 1 · registry result, not featured evidence
3.1%
NCT01539226 · Phase na · registry result, not featured evidence
11.7%100 mgb
NCT02275780 · Phase 3 · combination
show 44 more results
6.5%DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
4.2%DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
1.7%DOR/3TC/TDF Only (DOR/3TC/TDF From
NCT02403674 · Phase 3 · HIV · phase 3
6%DOR/3TC/TDF Only (From Day 1) at B
NCT02403674 · Phase 3 · HIV · phase 3
4.5%DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
5.2%DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
6.3%DOR/3TC/TDF Switch (Switch From EF
NCT02403674 · Phase 3 · HIV · phase 3
8.2%DOR/3TC/TDF Switch at Week 96 Base
NCT02403674 · Phase 3 · HIV · phase 3
—MK-1439A (DOR/3TC/TDF From Day 1)
NCT02403674 · Phase 3 · HIV · phase 3
0%Cohort 1: DOR
NCT03332095 · Phase 1/2
4.4%Cohort 2: DOR/3TC/TDF
NCT03332095 · Phase 1/2 · combination
10.6%100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
2%100 mg
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
25%
NCT04689737 · Phase 4 · registry result, not featured evidence
—DOR/ISL
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
4.3%DOR/ISL: Base Study Week 0 - Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
6.2%DOR/ISL: Base Study Week 48-Week 9
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
2.6%DOR/ISL: Base Study Week 96-Week 1
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
0%DOR/ISL: Open-Label Extension Week
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
1.5%DOR/ISL: Post-Treatment Follow-Up
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
6.4%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
5.3%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
2.1%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
0%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
2.7%100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
4.8%Group 1: DOR/ISL Weeks 0-48
NCT04223778 · Phase 3 · registry result, not featured evidence
4%Group 1: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
—Group 1: Doravirine/Islatravir (DO
NCT04223778 · Phase 3 · registry result, not featured evidence
3.7%Group 2: DOR/ISL Weeks 48-End of T
NCT04223778 · Phase 3 · registry result, not featured evidence
—DOR/ISL + ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
0%DOR/ISL+ART
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
0%DOR/ISL: Treatment Naive Cohort
NCT04295772 · Phase 2 · registry result, not featured evidence
0%DOR/ISL: Treatment Naive Cohort Ex
NCT04295772 · Phase 2 · registry result, not featured evidence
2.7%DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
0%DOR/ISL: Virologically Suppressed
NCT04295772 · Phase 2 · registry result, not featured evidence
10.2%100 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
7.3%200 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
2.3%50 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
10%25 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
0%
NCT04900974 · Phase 1 · registry result, not featured evidence
—
NCT02715700 · Phase 1 · registry result, not featured evidence · combination
0%200 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT01466985 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
25 mg DVR inserted once every 4 weeksa
metrorrhagia 55.1% (placebo 55.6%)
genitourinary chlamydia infection 20.5% (placebo 20.8%)
menorrhagia 19.7% (placebo 18.4%)
NCT01617096 · Phase 3 · monotherapy
show 9 more results
25 mg
infections 49.1%
reproductive system 20.9%
headache 3.5%
NCT02862171 · Phase 3
25 mg vaginal matrix ring
genitourinary chlamydia infection 8.4%
vaginal discharge 8%
vulvovaginitis trichomonal 5.9%
NCT02858037 · Phase 3 · registry result, not featured evidence
any event in soc 58.5%
any event in soc 32.4%
creatinine renal clearance decreased 30.3%
NCT03593655 · Phase 2 · registry result, not featured evidence
metrorrhagia 20.5% (placebo 26.1%)
vaginal discharge 15.1% (placebo 34.8%)
bacterial vaginosis 12.3% (placebo 8.7%)
NCT02028338 · Phase 2 · registry result, not featured evidence
vaginal discharge 11.1% (placebo 12.5%)
upper respiratory tract infection 8.3% (placebo 12.5%)
vaginal odour 6.9% (placebo 0%)
NCT02010593 · Phase 2 · registry result, not featured evidence
vaginitis bacterial 16.3% (placebo 11.9%)
vaginal candidiasis 9.3% (placebo 0%)
abdominal pain lower 4.7% (placebo 0%)
NCT00799058 · Phase 1/2 · registry result, not featured evidence
vaginitis bacterial 34.9% (placebo 11.9%)
vulvovaginal pruritus 9.3% (placebo 4.8%)
headache 7% (placebo 7.1%)
NCT00799058 · Phase 1/2 · registry result, not featured evidence
diarrhoea 11.1% (placebo 22.2%)
insomnia 11.1% (placebo 0%)
anal pruritus 5.6% (placebo 0%)
NCT03239483 · Phase 1 · registry result, not featured evidence
gynaecological chlamydia infection 32.7% (placebo 32.7%)
metrorrhagia 27% (placebo 29.6%)
genital infection female 23% (placebo 19.3%)
NCT01539226 · Phase na · registry result, not featured evidence
100 mgb
diarrhoea 18.8%
upper respiratory tract infection 16.7%
headache 16.4%
NCT02275780 · Phase 3 · combination
show 33 more results
nasopharyngitis 13.7%
upper respiratory tract infection 7.2%
headache 6.2%
NCT02403674 · Phase 3 · HIV · phase 3
headache 15.9%
diarrhoea 13.7%
nasopharyngitis 13.7%
NCT02403674 · Phase 3 · HIV · phase 3
nasopharyngitis 9.7%
upper respiratory tract infection 7.1%
diarrhoea 6.3%
NCT02403674 · Phase 3 · HIV · phase 3
dizziness 38.2%
diarrhoea 15.9%
headache 15.4%
NCT02403674 · Phase 3 · HIV · phase 3
aspartate aminotransferase increased 22.2%
blood alkaline phosphatase increased 11.1%
blood glucose increased 11.1%
NCT03332095 · Phase 1/2
glomerular filtration rate decreased 55.6%
alanine aminotransferase increased 46.7%
blood creatinine increased 46.7%
NCT03332095 · Phase 1/2 · combination
100 mg
creatinine renal clearance decreased 10.6%
low density lipoprotein increased 6.4%
abdominal pain upper 2.1%
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
100 mg
creatinine renal clearance decreased 8.2%
aspartate aminotransferase increased 4.1%
alanine aminotransferase increased 2%
NCT04636437 · Phase 4 · registry result, not featured evidence · combination
vomiting 25%
headache 12.5%
NCT04689737 · Phase 4 · registry result, not featured evidence
headache 8.1%
covid-19 5.9%
arthralgia 5%
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
covid-19 13.1%
lymphocyte count decreased 10.5%
cd4 lymphocytes decreased 9.2%
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
lymphocyte count decreased 32.3%
cd4 lymphocytes decreased 23.7%
covid-19 12.4%
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
lymphocyte count decreased 15.9%
cd4 lymphocytes decreased 11.4%
covid-19 1.5%
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
covid-19 2.6%
nasopharyngitis 2%
diarrhoea 1%
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
100 mg/0.75 mg
covid-19 14.1%
headache 10.4%
lymphocyte count decreased 9.1%
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
100 mg/0.75 mg
lymphocyte count decreased 24.1%
cd4 lymphocytes decreased 10.5%
covid-19 7.5%
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
100 mg/0.75 mg
lymphocyte count decreased 17.1%
cd4 lymphocytes decreased 8.2%
upper respiratory tract infection 2.7%
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
100 mg/0.75 mg
lymphocyte count decreased 14.3%
accidental overdose 0%
arthralgia 0%
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
100 mg/0.75 mg
upper respiratory tract infection 6.3%
insomnia 1.8%
headache 0.9%
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
headache 10.7%
accidental overdose 7.1%
covid-19 5.4%
NCT04223778 · Phase 3 · registry result, not featured evidence
lymphocyte count decreased 20.2%
cd4 lymphocytes decreased 14%
covid-19 13%
NCT04223778 · Phase 3 · registry result, not featured evidence
covid-19 17.5%
lymphocyte count decreased 13.5%
cd4 lymphocytes decreased 12%
NCT04223778 · Phase 3 · registry result, not featured evidence
blood creatine phosphokinase increased 28.6% (placebo 14.3%)
diarrhoea 28.6% (placebo 14.3%)
anaemia 14.3% (placebo 0%)
NCT04233216 · Phase 3 · registry result, not featured evidence · combination
dizziness 33.3%
dyspepsia 33.3%
headache 33.3%
NCT04295772 · Phase 2 · registry result, not featured evidence
covid-19 100%
adjustment disorder 0%
back pain 0%
NCT04295772 · Phase 2 · registry result, not featured evidence
oropharyngeal pain 10.8%
cough 8.1%
nasal congestion 8.1%
NCT04295772 · Phase 2 · registry result, not featured evidence
cough 28.6%
oropharyngeal pain 21.4%
rhinorrhoea 21.4%
NCT04295772 · Phase 2 · registry result, not featured evidence
100 mg
nasopharyngitis 17.6%
diarrhea 14.8%
dizziness 14.8%
NCT01632345 · Phase 2 · registry result, not featured evidence
200 mg
nasopharyngitis 29.3%
nausea 22%
headache 17.1%
NCT01632345 · Phase 2 · registry result, not featured evidence
50 mg
abnormal dreams 20.9%
nausea 16.3%
headache 14%
NCT01632345 · Phase 2 · registry result, not featured evidence
25 mg
diarrhea 25%
fatigue 17.5%
influenza 15%
NCT01632345 · Phase 2 · registry result, not featured evidence
200 mg
diarrhoea 33.3% (placebo 0%)
headache 33.3% (placebo 33.3%)
abdominal pain 16.7% (placebo 0%)
NCT01466985 · Phase 1 · registry result, not featured evidence
25 mg
alanine aminotransferase increased 16.7% (placebo 0%)
aspartate aminotransferase increased 16.7% (placebo 0%)
decreased appetite 16.7% (placebo 0%)
NCT01466985 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.
  2. bPopulation comparability has not been reviewed for 24 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Dapivirine

HIV-1 Incidence Rate Per 100 PY 2.7 count @ 56.5wk25 mg vaginal matrix ring
event rate · count
No placebo or comparator arm
NCT02858037 · Phase 3 · registry result, not featured evidence
HIV-2 Seroconversion 0% (n=1302) vs 0% (n=650) placebo @ 104wk
event count · % of participants
NCT01539226 · Phase na · registry result, not featured evidence · converted to % from 0 Participants as posted

Doravirine

HIV-1 RNA Less Than 50 Copies 83.8% (n=383) vs 79.9% (n=383) Daurunavir + Ritonavir @ 48wk100 mg
responder rate · % of participants
NCT02275780 · Phase 3 · combination
show 3 more results
73.1% (n=379) vs 66% (n=376) Daurunavir + Ritonavir @ 96wk100 mg
NCT02275780 · Phase 3 · combination
84.3% (n=364) vs 80.8% (n=364) ATRIPLA @ 48wk
NCT02403674 · Phase 3 · HIV · phase 3
77.5% (n=364) vs 73.6% (n=364) ATRIPLA @ 96wk
NCT02403674 · Phase 3 · HIV · phase 3
CD4+ 192.7 vs 185.6 Daurunavir + Ritonavir cells/uL @ 48wk100 mg
absolute change · cells/uL
NCT02275780 · Phase 3 · combination
show 14 more results
224.1 vs 206.7 Daurunavir + Ritonavir cells/uL @ 96wk100 mg
NCT02275780 · Phase 3 · combination
133.6 vs 121.1 Efavirenz cells/uL @ 24wk100 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
152.3 vs 146 Efavirenz cells/uL @ 24wk100 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
191.9 vs 194.5 Efavirenz cells/uL @ 48wk100 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
259.2 vs 263.6 Efavirenz cells/uL @ 96wk100 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
140.7 vs 121.1 Efavirenz cells/uL @ 24wk200 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
182.4 vs 233.5 BIC/FTC/TAF cells/uL @ 48wk100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
217.05 vs 319.92 BIC/FTC/TAF cells/uL @ 96wk100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
239.6 vs 350.9 BIC/FTC/TAF cells/uL @ 144wk100 mg/0.75 mg
NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3
112.9 vs 121.1 Efavirenz cells/uL @ 24wk50 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
154.1 vs 121.1 Efavirenz cells/uL @ 24wk25 mg
NCT01632345 · Phase 2 · registry result, not featured evidence
-19.66 vs 40.51 BIC/FTC/TAF cells/uL @ 48wk
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
5.36 vs 62.67 BIC/FTC/TAF cells/uL @ 96wk
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
0.48 vs 66.25 BIC/FTC/TAF cells/uL @ 144wk
NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3
LDL-C -4.51 vs 9.92 Daurunavir + Ritonavir mg/dL @ 48wk100 mg
absolute change · mg/dL
Change from Baseline
NCT02275780 · Phase 3 · combination
Non-HDL-C Change mg/dL -5.3 vs 13.75 Daurunavir + Ritonavir mg/dL @ 48wk100 mg
absolute change · mg/dL
Change from Baseline
NCT02275780 · Phase 3 · combination
HDL-C Change mg/dL 3.94 vs 4.15 Daurunavir + Ritonavir mg/dL @ 48wk100 mg
absolute change · mg/dL
Change from Baseline
NCT02275780 · Phase 3 · combination
Total Cholesterol Change mg/dL -1.37 mg/dL @ 48wk100 mg
absolute change · mg/dL
No placebo or comparator arm
Change from Baseline
NCT02275780 · Phase 3 · combination
Triglyceride Change mg/dL -3.14 vs 21.97 Daurunavir + Ritonavir mg/dL @ 48wk100 mg
absolute change · mg/dL
Change from Baseline
NCT02275780 · Phase 3 · combination
HIV-1 RNA Less Than 40 Copies 83.3% (n=383) vs 79.1% (n=383) Daurunavir + Ritonavir @ 48wk100 mg
responder rate · % of participants
NCT02275780 · Phase 3 · combination
show 3 more results
72% (n=379) vs 64.4% (n=376) Daurunavir + Ritonavir @ 96wk100 mg
NCT02275780 · Phase 3 · combination
83.8% (n=364) vs 79.7% (n=364) ATRIPLA @ 48wk
NCT02403674 · Phase 3 · HIV · phase 3
76.1% (n=364) vs 72.8% (n=364) ATRIPLA @ 96wk
NCT02403674 · Phase 3 · HIV · phase 3
CD4+ 198.4% (n=344) vs 188.4% (n=329) ATRIPLA @ 48wk
absolute change · percentage points
NCT02403674 · Phase 3 · HIV · phase 3
show 3 more results
237.7% (n=337) vs 223% (n=311) ATRIPLA @ 96wk
NCT02403674 · Phase 3 · HIV · phase 3
-0.7% (n=313) vs 8.7% (n=311) Baseline Antiretroviral Therapy (ART) @ 48wk
NCT04223778 · Phase 3 · registry result, not featured evidence
5.29% (n=289) vs 0.16% (n=285) Baseline Antiretroviral Therapy (ART) @ 96wk
NCT04223778 · Phase 3 · registry result, not featured evidence
LDL-C -1.58% (n=330) vs 8.74% (n=305) ATRIPLA @ 48wk
percent change · % of baseline
NCT02403674 · Phase 3 · HIV · phase 3
Non-HDL-C -3.83% (n=333) vs 13.26% (n=314) ATRIPLA @ 48wk
percent change · % of baseline
NCT02403674 · Phase 3 · HIV · phase 3
Total Cholesterol -1.97% (n=333) vs 21.77% (n=314) ATRIPLA @ 48wk
percent change · % of baseline
NCT02403674 · Phase 3 · HIV · phase 3

+ 43 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dapivirine's landscape · Doravirine's landscape